Navigation Links
Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C
Date:8/19/2009

nts with few or no reported risk factors for stroke, including patients less than 45 years of age. Because these are spontaneous reports, estimates of frequency cannot be made and causal relationship between interferon alfa-based therapies and these events is difficult to establish.

The most common adverse events reported for PEGASYS and COPEGUS combination therapy observed in clinical trials were fatigue/asthenia (65 percent), headache (43 percent), pyrexia (41 percent), myalgia (40 percent), irritability/anxiety/nervousness (33 percent), insomnia (30 percent), alopecia (28 percent), neutropenia (27 percent), nausea/vomiting (25 percent), rigors (25 percent), anorexia (24 percent), injection site reaction (23 percent), arthralgia (22 percent), depression (20 percent), pruritus (19 percent) and dermatitis (16 percent).

Serious adverse events in hepatitis C trials included neuropsychiatric disorders (homicidal ideation, suicidal ideation, suicide attempt, suicide, psychotic disorder and hallucinations), serious and severe bacterial infections (sepsis), bone marrow toxicity (cytopenia and rarely, aplastic anemia), cardiovascular disorders (hypertension, supraventricular arrhythmias and myocardial infarction), hypersensitivity (including anaphylaxis), endocrine disorders (including thyroid disorders and diabetes mellitus), autoimmune disorders (including idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, psoriasis, lupus, rheumatoid arthritis and interstitial nephritis), pulmonary disorders (dyspnea, pneumonia, bronchiolitis obliterans, interstitial pneumonitis and sarcoidosis), colitis (ulcerative and hemorrhagic/ischemic colitis), pancreatitis, and ophthalmologic disorders (decrease or loss of vision, retinopathy including macular edema and retinal thrombosis/hemorrhages, optic neuritis and papilledema).

Adverse reactions reported during post-approval use of PEGASYS therapy, with and w
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Rochester Medical Reports Third Quarter Results
2. Roche Cardiac 200 Offers Rapid Cardiac Diagnostics for the Point of Care
3. Rochester Medical Announces Third Quarter 2009 Earnings Conference Call July 30, 2009
4. Enigma Diagnostics Announces Signing of Patent Licenses With Roche Molecular Systems, Inc.
5. Roche Diabetes Care Announces Unique Coaching Program for Diabetes Educators as Part of Long-Term Commitment to Fight the Disease
6. NJLRA Statement in Response to Roches Discontinuation of Accutane(R)
7. Orochem Technologies Acquires Oligonet, a Custom Oligo Synthesis Business
8. Purple Communications Dream Bigger Initiative Honors Rochester Physician and Deaf Community Trailblazer
9. Rochester Medical Corporation Set to Join Russell 3000 Index
10. Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack
11. Raptor Pharmaceuticals to Collaborate with Roche on Therapeutic Delivery Across Blood-Brain Barrier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... (PRWEB) July 11, 2014 Los ... announces that he uses mini and full mouth implants ... the defining feature that distinguishes dental implants from other ... addition to the crowns. This alone prevents the long-term ... also offer advantages related to comfort, appearance and systemic ...
(Date:7/11/2014)... Maureen Salamon HealthDay ... -- For the millions of women who can,t cough, ... testing a treatment that uses stem cells to regenerate ... European researchers found that injecting stem cells isolated from ... in all participants within a year. Stress ...
(Date:7/11/2014)... July 11, 2014 Recent research findings regarding ... the atmosphere, and how water affects human bodies. That was ... Pollack, during an interview on the Sharon Kleyne Hour Power ... , Gerald Pollack, PhD, is a Professor of Bioengineering ... Fourth Phase of Water (Ebner & Sons, 2013). ...
(Date:7/11/2014)... July 11, 2014 Shoulder instability is ... of return to play has not been regularly determined ... Orthopaedic Society for Sports Medicine’s ( AOSSM ) Annual ... is approximately 90 percent no matter what the stabilization ... success rate of return to play following shoulder stabilization ...
(Date:7/11/2014)... reconstructions occur more than 200,000 times a year, but ... ligament may determine how long you stay in the ... Annual Meeting of the American Orthopaedic Society of Sports ... that in a young athletic population, allografts (tissue harvested ... (tissue harvested from the patient)," said Craig R. Bottoni, ...
Breaking Medicine News(10 mins):Health News:Dental Implant Dentist, Kevin Sands DDS, Now Uses Mini and Full Mouth Implants to Replace Missing Teeth 2Health News:Stem Cells May Ease Urinary Incontinence, Study Says 2Health News:Stem Cells May Ease Urinary Incontinence, Study Says 3Health News:Recent Fourth Phase Water Discoveries Alter Basic Understanding of Life, Claims Researcher on Sharon Kleyne Hour 2Health News:Recent Fourth Phase Water Discoveries Alter Basic Understanding of Life, Claims Researcher on Sharon Kleyne Hour 3Health News:Stabilizing Shoulder Surgery Helps NFL Players Return to the Game 2Health News:ACL reconstructions may last longer with autografts 2
... spikes a high fever, sometimes as high as 104 or ... emergency room, the hospital runs test after test, specialists are ... though no one knows how many go through ... arent accompanied by any obvious symptoms and dont respond to ...
... BUFFALO, N.Y. -- For a rich source of stem cells ... clinicians may one day look no further than the hair ... this month by University at Buffalo engineers. , ... new blood vessels or regenerating new skin tissue using stem ...
... Governor Edward G.,Rendell today released the text of his ... deadline for MCare fund assessment payments:, Dear Health ... that the state was in a unique,position to extend ... to affordable health care for hundreds of thousands of ...
... THE GOVERNMENT CURB AN OVERLY AGGRESSIVE VACCINATION SCHEDULE ... 28 Parents of children who,regressed into autism ... health officials may at last be catching on ... article published on Huffington Post by investigative journalist,David ...
... currently Dean of Research and Graduate Education in the ... University (JHU), has,been appointed Chief Executive Officer and Executive ... the,position on July 1, 2008. A published author in ... JHU and at JHU has served,as department chair of ...
... warn doctors early to change treatments , , FRIDAY, March ... they may have found a blood marker that denotes ... The researchers found an increase in the CD163+/CD16+ monocyte ... virus (HIV), according to a study published in the ...
Cached Medicine News:Health News:Mysterious fevers of unknown origin: Could surgery be a cure? 2Health News:Stem cells from hair follicles may help 'grow' new blood vessels 2Health News:Governor Rendell Writes to Physicians to Explain MCare Fund Assessment Deadline 2Health News:MITOCHONDRIAL DYSFUNCTION, VACCINES AND AUTISM: 1 in 50 Children Could Be at Risk 2Health News:Hauptman-Woodward Appoints Dr. Eaton Lattman CEO and Executive Director 2Health News:Hauptman-Woodward Appoints Dr. Eaton Lattman CEO and Executive Director 3Health News:Biomarker May Signal HIV Progression 2
(Date:7/10/2014)... 2014  RESMED INC. (NYSE: RMD ) today ... year ended June 30, 2014 results on Thursday, July 31, ... press release with ResMed,s results will be issued after 1:00 ... webcast to discuss operating results and future outlook. ... US Pacific Time and the live webcast of the call ...
(Date:7/10/2014)... Mass. , July 10, 2014  Decision ... of surveyed infectious disease (ID) specialists are willing ... Company,s Orbactiv (oritavancin) for use as OPAT, approximately ... prescribe these agents to their hospital inpatients. However, ... of OPAT patients are initiated on OPAT following ...
(Date:1/15/2014)... -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry Report, 2013-2015" ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting from aging ... China,s orthopedic instrument industry has seen rapid ... from 3.28 billion yuan in 2006 to 9.85 billion ...
Breaking Medicine Technology:ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 2Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 3Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 4Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 5Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 6Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 7Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 8Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 9Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 10Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 11Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 12Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 13Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 14Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 15Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 16Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 17Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 18Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 19Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 20Abbott to Collaborate With GSK on Molecular Diagnostic Test to Select Candidate Patients for Future Skin Cancer Immunotherapy 2Abbott to Collaborate With GSK on Molecular Diagnostic Test to Select Candidate Patients for Future Skin Cancer Immunotherapy 3Abbott to Collaborate With GSK on Molecular Diagnostic Test to Select Candidate Patients for Future Skin Cancer Immunotherapy 4Abbott to Collaborate With GSK on Molecular Diagnostic Test to Select Candidate Patients for Future Skin Cancer Immunotherapy 5Abbott to Collaborate With GSK on Molecular Diagnostic Test to Select Candidate Patients for Future Skin Cancer Immunotherapy 6Abbott to Collaborate With GSK on Molecular Diagnostic Test to Select Candidate Patients for Future Skin Cancer Immunotherapy 7Abbott to Collaborate With GSK on Molecular Diagnostic Test to Select Candidate Patients for Future Skin Cancer Immunotherapy 8
The major innovation in posterior stabilized (PS) knee design. Improve patellofemoral kinematics. Reduce wear rate potential. Increase resistance to posterior tibial dislocation. Achieve at least 120...
... provides the adaptability surgeons need to make ... other way around. The wide selection of ... components allow surgeons to address the unexpected ... all with one instrument set. For cruciate ...
... minimally invasive uni-compartmental knee replacement is an ... surgery. This procedure provides patients with a ... knee.,Arthritis of the knee often results in ... quality of life and even depression. Orthopedic ...
... The Genesis II® Total Knee System will ... far more is possible with less - ... while fully addressing both clinical and cost ... these design goals, giving surgeons creative solutions ...
Medicine Products: